Tenax Therapeutics

NEWS

Business

BioSpace Movers & Shakers, Feb. 4

Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

February 3, 2022

9 min read

Alex Keown

Business

New CEOs Named at Two Biopharma Companies

Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.

July 8, 2021

2 min read

Vanessa Doctor, RN

IN THE PRESS

Bio NC

Tenax Therapeutics Announces Reverse Stock Split - Jan 04, 2023

January 4, 2023

4 min read

Bio NC

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 10, 2022

6 min read

Bio NC

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

September 15, 2022

6 min read

Bio NC

Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

May 25, 2022

8 min read

Bio NC

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 23, 2022

6 min read

Deals

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 18, 2022

7 min read

Business

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

March 31, 2022

10 min read

Bio NC

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

March 30, 2022

6 min read

Business

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

January 31, 2022

6 min read

Bio NC

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

January 12, 2022

7 min read

JOBS